^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - B-Cell Lymphomas
Published date:
04/30/2024
Excerpt:
Mantle Cell Lymphoma...CAR T-cell therapy...Lisocabtagene maraleucel (CD19-directed)
